EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

SMD100_SAINTMED (SMD100) fair value: what the stock is really worth

As of Sep 24, 2026: fair value of SMD100_SAINTMED THB 1.12, price THB 1.76, upside -36.4%, quality 44 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · TH

SS Thin data Sep 24, 2026

SMD100_SAINTMED

SMD100 · BK

Weakest SetupStrongly overvalued and low quality.

!Fair value 1.12 THB · Strongly overvalued (−36%)
!Quality 44/100
!Weak Growth (revenue 5y +6.6 %/yr)
!Thin margins · 0.7% net margin (TTM)
!Low debt · negative free cash flow
·3.41% dividend yield
!Trails peers (5/13)
!Narrow moat 20/100
!Evidence only low, so the estimate is less certain
!Weak on past: 4 out of 100
Watch SMD100_SAINTMED for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

10.72 THB 1.07 THB Fair Value 1.12 THB Jun 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range 1.07 THB – 10.72 THB · fair‑value band 0.8400 THB – 1.36 THB · the 1.76 THB price screens above the 1.12 THB fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.

Follow SMD100_SAINTMED in your weekly email

Every Wednesday you see whether SMD100_SAINTMED is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

SMD Rise Public Company Limited engages in the import and distribution of medical devices, equipment, and supplies in Thailand. The company is involved in providing sleep testing services; and rental, hire purchase, and leasing of the medical equipment, as well as offers wellness equipment services.

Show more

SMD Rise Public Company Limited engages in the import and distribution of medical devices, equipment, and supplies in Thailand. The company is involved in providing sleep testing services; and rental, hire purchase, and leasing of the medical equipment, as well as offers wellness equipment services. It also imports and distributes products related to radiology and other similar medical products. In addition, the company designs and develops software and information technology systems. Further, it imports and distributes automated medication dispensing machines, pharmaceutical products, medical robots, vascular technologies and equipment, and other related devices. The company was formerly known as SaintMed Public Company Limited and changed its name to SMD Rise Public Company Limited in January 2025. The company was founded in 1998 and is based in Nonthaburi, Thailand.

Stock analysis

SMD100_SAINTMED (SMD100) currently trades at 1.76 THB, while our model-based Fair Value estimate is 1.12 THB, implying the stock looks roughly 57.1% overvalued today.

Show more

Valuation

Bull case: the Asset-Based group reads highest at a median of 2.31 THB per share, and 6 of the 15 models we run sit above the 1.76 THB price.

Bear case: the Earnings-Based group reads lowest at 0.5500 THB, and 9 of the 15 models stay below the price. Evidence for this calculation is low.

Scenario range: 0.8400 THB (bear) to 1.36 THB (bull), the price of 1.76 THB sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 44/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

SMD100_SAINTMED reported revenue of 910M THB in FY2025 versus 1.6B THB in FY2021, a compound −13.4%/yr. Reported net income was 10.6M THB in FY2025, compounding −57.3%/yr from FY2021.

Key figures

Market cap 366M THB (≈ $10.9M) · P/E ratio 58.7 · P/S ratio 0.68 · EPS (TTM) 0.0300 THB · Dividend yield 3.4% · Net margin 1.2% · Return on equity 0.9% · Return on assets (EBIT) 15.5%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (low confidence).

What moves the price

The share trades about 49% below its 52-week high and 64% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 35% fair-value upside, at −36%, SMD100 screens richer than that median.

Fair Value models

Bear 0.8400 THB Fair Value 1.12 THB Bull 1.36 THB
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
EPV 1.11 THB 1.27 THB 1.40 THB 74
Residual Income 2.35 THB 2.19 THB 1.62 THB 74
Owner Earnings 1.10 THB 1.81 THB 2.96 THB 72
All 15 models by family
DCF Models
Owner Earnings 1.10 THB 1.81 THB 2.96 THB 72
Earnings-Based
Graham-Dodd 0.3500 THB 1.50 THB 2.04 THB 62
Lynch FV 0.3800 THB 0.5500 THB 0.7100 THB 59
PEG = 1.0 0.3800 THB 0.5500 THB 0.7100 THB 55
EPV 1.11 THB 1.27 THB 1.40 THB 74
Multiples
P/E Multiple 0.8400 THB 1.12 THB 1.41 THB 63
P/S Multiple 0.6500 THB 0.8700 THB 1.09 THB 58
P/B Multiple 0.6500 THB 0.8700 THB 1.09 THB 55
EV/EBIT 2.39 THB 3.16 THB 3.92 THB 66
EV/EBITDA 4.30 THB 5.70 THB 7.10 THB 67
EV/Revenue 1.74 THB 2.44 THB 3.14 THB 54
Asset-Based
NCAV (Graham) 1.72 THB 2.31 THB 3.45 THB 54
Economic Profit
Residual Income 2.35 THB 2.19 THB 1.62 THB 74
ROIC Compounder 1.11 THB 1.27 THB 1.40 THB 70
Growth Earnings
Growth-Adj P/E 0.6600 THB 0.9400 THB 1.22 THB 65

Open the full fair value analysis →

Notify me when SMD100 reaches fair value

Put SMD100 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 44/100

Of which business quality 42 · Market factors (momentum, volatility) 44

Profitability 29
Margins and returns on capital today
Quality Growth 35
Are margins and returns improving?
Cashflow 0
Earnings quality: real cash, not paper profit
Fin. Strength 46
Balance sheet, leverage, solvency risk
Investment 86
Disciplined investing over empire-building
Low Volatility 69
Calm price path (market factor)
Momentum 45
Price trend over the last 3–12 months (market factor)
52W Momentum 13
Distance to the 52-week high (market factor)
Net Issuance 90
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 40/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+14.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−23.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.6%
Start year 2020 (pandemic)
Revenue growth 9 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.4%
What shareholders gained per year (last 5 years), in THB ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in THB: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−28.4%
Earnings growth per share plus dividend.
Earnings per share, growth per year−31.8%
Dividend (yield on the price)3.4%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−32% vs −17%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.16% → 4%
Start year 2020 (pandemic)

SMD100 screens 57% overvalued. Compare with McKesson Corporation →

Compare SMD100_SAINTMED with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Distribution · 83 stocks

Beats the industry median on 5/13 measures
Overall it trails its industry peers.
Valuation
Quality Score 44 · Bottom 25%
Fair Value upside −36% · Bottom 25%
Profitability
Return on equity (TTM) 1% · Bottom 25%
Return on assets 2% · Below median
Net margin (TTM) 1% · Below median
Operating margin (TTM) −16% · Bottom 25%
Growth and dividend
Revenue growth 14% · Top 25%
Dividend yield (TTM) 3.4% · Above median
Balance sheet
Debt / equity 0.04× · Below median

Valuation Multiplesvs Medical Distribution median · lower = cheaper

P/E (TTM) 58.7× · Priciest 25%
P/B 0.51× · Cheapest 25%
P/S (TTM) 0.39× · Pricier than median
EV/EBITDA 4.8× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 44
FUTURE (revenue growth)68 · sector 15
PAST (return on equity)4 · sector 27
HEALTH (low debt)98 · sector 96
DIVIDEND (yield)68 · sector 59

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Distribution stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
McKesson Corporation MCK $880.50 $819.31 −7%
Cencora, Inc COR $312.28 $211.07 −32%
Cardinal Health, Inc CAH $221.27 $141.77 −36%
Henry Schein, Inc HSIC $87.43 $76.86 −12%
Shanghai Pharmaceuticals Holding 601607 ¥16.06 ¥42.67 +166%
Sinopharm Group 1099 HK$15.06 HK$58.89 +291%
Galenica AG GALE CHF 83.45 CHF 61.79 −26%
Guangzhou Baiyunshan Pharmaceutical Holdings 600332 ¥19.67 ¥26.64 +35%
Jointown Pharmaceutical Group 600998 ¥4.89 ¥9.84 +101%
China National Medicines Corporation 600511 ¥26.11 ¥58.47 +124%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

SMD100_SAINTMED · Fair Value
1.12 THB −57%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "SMD100_SAINTMED Fair Value". https://www.fairvalue-calculator.com/stock/SMD100

Frequently asked questions

Is SMD100_SAINTMED (SMD100) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 1.12 THB versus a price of 1.76 THB, about −36% upside (overvalued).
What is the fair value of SMD100?
Our model-based fair value for SMD100_SAINTMED is 1.12 THB (as of Sep 24, 2026), built from audited fundamentals. The current price: 1.76 THB.
What is the quality score of SMD100?
SMD100_SAINTMED has a Quality Score of 44/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for SMD100_SAINTMED (SMD100)?
Our model-based price target is the fair value of 1.12 THB (as of Sep 24, 2026) from 15 valuation models. Cautious scenario 0.8400 THB, optimistic scenario 1.36 THB. It is a calculation from audited fundamentals, not an analyst target.
What is the SMD100_SAINTMED stock forecast for 2026?
Our models put fair value at 1.12 THB, about −36% upside versus a price of 1.76 THB (overvalued). Cautious scenario 0.8400 THB, optimistic scenario 1.36 THB. The calculation is refreshed regularly with new filings.
What is the revenue of SMD100_SAINTMED (SMD100)?
SMD100_SAINTMED reported trailing-twelve-month revenue of about 931M THB (latest available figure, as of Sep 24, 2026).
Does SMD100_SAINTMED pay a dividend?
SMD100_SAINTMED currently shows a dividend yield of about 3.41% relative to its recent price (as of Sep 24, 2026).
What is the intrinsic value of SMD100_SAINTMED (SMD100)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For SMD100_SAINTMED it is 1.12 THB per share (as of Sep 24, 2026), against a price of 1.76 THB. It is the blended result of 15 valuation models (cash flow, earnings, asset, dividend).
Is SMD100_SAINTMED stock overvalued or undervalued in 2026?
As of Sep 24, 2026, SMD100 trades above its calculated fair value: price 1.76 THB, fair value 1.12 THB, a gap of about −36% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of SMD100?
No. The price is what the market pays today (1.76 THB); the fair value is what the company's own numbers justify (1.12 THB). For SMD100_SAINTMED the two are 0.6400 THB per share apart. That gap is exactly why we show both numbers side by side.
How much is SMD100_SAINTMED worth?
The market values SMD100_SAINTMED at about 366M THB (market capitalisation, as of Sep 24, 2026). Per share that is 1.76 THB; our models calculate a fair value of 1.12 THB per share.
What do the bullish and bearish scenarios say about SMD100?
Our models span a range for SMD100_SAINTMED: cautious scenario 0.8400 THB, base 1.12 THB, optimistic 1.36 THB per share (as of Sep 24, 2026, price 1.76 THB). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of SMD100?
SMD100_SAINTMED trades at a price-to-earnings ratio of 58.7 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 1.12 THB is built from several models across several years. Other multiples: P/B 0.5, P/S 0.4, EV/EBITDA 4.8.
How solid is the balance sheet of SMD100_SAINTMED (SMD100)?
Balance-sheet figures for SMD100_SAINTMED (as of Sep 24, 2026): return on equity 0.9%, debt of 0.04 per unit of equity. They feed the Quality Score of 44/100, which measures business quality independently of the share price.
How far is SMD100 from its 52-week high?
SMD100_SAINTMED trades at 1.76 THB, about 49% below its 52-week high of 3.48 THB and 64% above the low of 1.07 THB (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of 1.12 THB is for.
Which stocks are comparable to SMD100_SAINTMED?
From the same area (Healthcare) we also value McKesson Corporation, Cencora, Inc, Cardinal Health, Inc, Henry Schein, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is SMD100_SAINTMED stock attractive at the current price?
The data as of Sep 24, 2026: price 1.76 THB, calculated fair value 1.12 THB (−36%), Quality Score 44/100, from 15 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of SMD100 calculated?
We run SMD100_SAINTMED through 15 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 1.12 THB, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0 % above its aggregate fair value. SMD100_SAINTMED itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of SMD100_SAINTMED (SMD100)?
The closing price on Sep 24, 2026 was 1.76 THB. Our model-based fair value is 1.12 THB, about −36% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with SMD100_SAINTMED right now?
The price sits above even our optimistic bull case (1.36 THB). The favourable scenario is already priced in. Weak quality (44/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of SMD100_SAINTMED

How large is the market capitalisation of SMD100_SAINTMED (SMD100)?
The market capitalisation of SMD100_SAINTMED is 366M THB (≈ $10.9M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of SMD100_SAINTMED (SMD100)?
The price-to-sales ratio of SMD100_SAINTMED is 0.68 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of SMD100_SAINTMED (SMD100)?
Earnings per share at SMD100_SAINTMED are 0.0300 THB (price ÷ EPS = P/E 58.7). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of SMD100_SAINTMED (SMD100)?
The dividend yield of SMD100_SAINTMED is 3.4% (payout 200%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of SMD100_SAINTMED (SMD100)?
The net margin of SMD100_SAINTMED is 1.2% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of SMD100_SAINTMED (SMD100)?
The return on equity (ROE) of SMD100_SAINTMED is 0.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of SMD100_SAINTMED (SMD100)?
On an EBIT basis the return on assets of SMD100_SAINTMED is 15.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of SMD100_SAINTMED (SMD100)?
The operating margin of SMD100_SAINTMED is −16.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at SMD100_SAINTMED (SMD100)?
Revenue at SMD100_SAINTMED is growing +13.5% versus a year earlier (3y avg −23.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at SMD100_SAINTMED (SMD100)?
Earnings per share at SMD100_SAINTMED are growing +21.5% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does SMD100_SAINTMED (SMD100) generate?
The free cash flow of SMD100_SAINTMED is −153M THB (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does SMD100_SAINTMED (SMD100) carry?
The net debt of SMD100_SAINTMED is 193M THB (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch SMD100_SAINTMED in the live analysis

One click puts SMD100_SAINTMED on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.